Korea University faculty-founded venture company Jeronmed Co., Ltd. (Korea University Convergence Biotechnology Department Professor Lee Byeong-cheon, CEO) received approval to manufacture in vitro diagnostic medical devices from the Ministry of Food and Drug Safety in December 2024.
This approval is considered a significant achievement as it marks the first step towards commercializing GeronMed’s Redox platform (R2P2®) technology into the market through the development and manufacturing of biopharmaceutical materials and diagnostic reagent products.
Geronmed is an R&D company specializing in the development of biopharmaceutical materials and raw materials, and is developing biopharmaceutical preparations for disease monitoring and screening, as well as diagnostic reagent raw materials. The visible achievements made until obtaining the approval for the manufacturing of in vitro diagnostic medical devices were largely due to the long-term experience and development know-how of Vice President Lee Hyun-jung, a graduate of Korea University’s Graduate School of Biotechnology and Korea University’s College of Medicine, at global bio and global pharmaceutical companies, which served as an important starting point for Geronmed to grow into a global healthcare manufacturing company.
The in vitro diagnostic medical device manufacturing license acquired by JeronMed is significant in that it proves that the Redox platform technology can be innovatively utilized in the medical field, and by doing so, it accelerates commercialization through manufacturing and production in the medical market, thereby securing a position as a key technology powerhouse in the Korean biopharmaceutical materials market.
This manufacturing permit from the Ministry of Food and Drug Safety was achieved through the full support of Korea University’s Crimson Startup Support Group, Technology Commercialization Center, and Seoul Biohub, and through the startup growth support project of the Seoul Metropolitan Government’s SBA Seoul Economic Promotion Agency and the Ministry of SMEs and Startups.
Through this, JeronMed is expected to play an important role in the Korean biomedical startup ecosystem and the global healthcare industry.
- See more related articles
You must be logged in to post a comment.